These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 14982787)

  • 1. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.
    Leighton A; Gottlieb AB; Dorr MB; Jabes D; Mosconi G; VanSaders C; Mroszczak EJ; Campbell KC; Kelly E
    Antimicrob Agents Chemother; 2004 Mar; 48(3):940-5. PubMed ID: 14982787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of dalbavancin against methicillin-resistant Staphylococcus aureus in the rat granuloma pouch infection model.
    Jabés D; Candiani G; Romanó G; Brunati C; Riva S; Cavaleri M
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1118-23. PubMed ID: 15047510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tolerability of teicoplanin in healthy volunteers after single increasing doses.
    Del Favero A; Patoia L; Rosina R; Buniva G; Danese A; Bernareggi A; Molini E; Cavenaghi L
    Antimicrob Agents Chemother; 1991 Dec; 35(12):2551-7. PubMed ID: 1839759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.
    Shaw JP; Seroogy J; Kaniga K; Higgins DL; Kitt M; Barriere S
    Antimicrob Agents Chemother; 2005 Jan; 49(1):195-201. PubMed ID: 15616296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects.
    Scoble PJ; Owens RC; Puttagunta S; Yen M; Dunne MW
    Clin Drug Investig; 2015 Dec; 35(12):785-93. PubMed ID: 26458939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects.
    Cass RT; Brooks CD; Havrilla NA; Tack KJ; Borin MT; Young D; Bruss JB
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5874-80. PubMed ID: 21911572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose escalation study of the safety, tolerability, and pharmacokinetics of nemonoxacin (TG-873870), a novel potent broad-spectrum nonfluorinated quinolone, in healthy volunteers.
    Lin L; Chang LW; Tsai CY; Hsu CH; Chung DT; Aronstein WS; Ajayi F; Kuzmak B; Lyon RA
    Antimicrob Agents Chemother; 2010 Jan; 54(1):405-10. PubMed ID: 19884368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of dalbavancin in plasma and skin blister fluid.
    Nicolau DP; Sun HK; Seltzer E; Buckwalter M; Dowell JA
    J Antimicrob Chemother; 2007 Sep; 60(3):681-4. PubMed ID: 17631507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
    Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
    Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.
    James JK; Palmer SM; Levine DP; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):696-700. PubMed ID: 8851595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species.
    DeRyke CA; Sutherland C; Zhang B; Nicolau DP; Kuti JL
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3529-34. PubMed ID: 17065618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of teicoplanin upon multiple-dose intravenous administration of 3, 12, and 30 milligrams per kilogram of body weight to healthy male volunteers.
    Smithers JA; Kulmala HK; Thompson GA; Antony KK; Lewis EW; Ruberg SJ; Kenny MT; Dulworth JK; Brackman MA
    Antimicrob Agents Chemother; 1992 Jan; 36(1):115-20. PubMed ID: 1534211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses.
    Outman WR; Nightingale CH; Sweeney KR; Quintiliani R
    Antimicrob Agents Chemother; 1990 Nov; 34(11):2114-7. PubMed ID: 2149920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.
    Rouveix B; Jehl F; Drugeon H; Brumpt I; Caulin E
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2394-9. PubMed ID: 15215086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of dalbavancin, a novel semisynthetic lipoglycopeptide.
    Kim A; Kuti JL; Nicolau DP
    Expert Opin Investig Drugs; 2007 May; 16(5):717-33. PubMed ID: 17461743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human pharmacokinetics and rationale for once-weekly dosing of dalbavancin, a semi-synthetic glycopeptide.
    Dorr MB; Jabes D; Cavaleri M; Dowell J; Mosconi G; Malabarba A; White RJ; Henkel TJ
    J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii25-30. PubMed ID: 15750034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections.
    Jauregui LE; Babazadeh S; Seltzer E; Goldberg L; Krievins D; Frederick M; Krause D; Satilovs I; Endzinas Z; Breaux J; O'Riordan W
    Clin Infect Dis; 2005 Nov; 41(10):1407-15. PubMed ID: 16231250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers.
    Hoover R; Hunt T; Benedict M; Paulson SK; Lawrence L; Cammarata S; Sun E
    Clin Ther; 2016 Jan; 38(1):53-65. PubMed ID: 26718605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
    Persiani S; D'Amato M; Makovec F; Tavares IA; Bishai PM; Rovati LC
    Int J Clin Pharmacol Ther; 2002 May; 40(5):198-206. PubMed ID: 12051571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.